FIELD: biotechnology.
SUBSTANCE: invention relates to peptide immunogenic constructs of alpha-synuclein (α-Syn), and can be used medically to treat brain disease in an individual with synucleinopathy. Proposed peptide immunogenic constructs of α-Syn contain a B-cell epitope of α-Syn bound to a heterologous T-helper cell (Th) epitope directly or via a heterologous spacer.
EFFECT: invention ensures the production of peptide immunogenic constructs of α-Syn, which stimulate the formation of highly specific antibodies that cross-react with β-leaf of α-Syn in the form of monomers, oligomers and fibrils, but with not naturally occurring α-spiral of α-Syn, providing therapeutic immune responses in patients at risk of developing synucleinopathies.
17 cl, 28 dwg, 15 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TAU-PEPTIDE IMMUNOGENIC CONSTRUCTS | 2018 |
|
RU2798972C2 |
| PEPTIDE IMMUNOGENS TARGETING INTERLEUKIN 6 (IL-6) AND COMPOSITIONS THEREOF FOR IMMUNOTHERAPY OF DISEASES AFFECTED BY IMPAIRED IL-6 REGULATION | 2019 |
|
RU2780161C1 |
| IL-31 PEPTIDE IMMUNOGENS AND THEIR COMPOSITIONS FOR THE TREATMENT AND/OR PREVENTION OF ADOPIC DERMATITIS | 2018 |
|
RU2799440C2 |
| PEPTIDE IMMUNOGENS AND COMPOSITIONS CONTAINING SAID IMMUNOGENS TARGETING MEMBRANE-BOUND IGE FOR TREATING IGE-MEDIATED ALLERGIC DISEASES | 2017 |
|
RU2769983C2 |
| PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF ALZHEIMER-TYPE DEMENTIA | 2013 |
|
RU2811687C2 |
| ANTIBODIES TO ALPHA-SYNUCLEIN AND OPTIONS OF THEIR USE | 2019 |
|
RU2812765C2 |
| MONOCLONAL ANTIBODIES TO ALPHA-SYNUCLEIN FOR PREVENTING TAU-PROTEIN AGGREGATION | 2017 |
|
RU2760334C2 |
| ANTIBODIES | 2018 |
|
RU2798399C2 |
| AGENTS, APPLICATION WAYS AND METHODS FOR TREATING SYNUCLEOPATHY | 2016 |
|
RU2765303C2 |
| VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCTION OF ANTIBODY EXPRESSION | 2017 |
|
RU2813282C2 |
